RXI-231 is an sd-rxRNA compound developed to target Tyrosinase (TYR), which is an important enzyme in the synthesis of melanin, the pigment that gives human skin, hair and eyes their color.
The compound lead to a visible reduction of pigmentation in melanocytes in a 3-dimensional tissue culture model of human epidermis.
RXI-185 is an sd-rxRNA compound developed to target collagenase matrix metalloproteinase 1 (MMP1)
It is involved in the breakdown of extracellular matrix that specifically cleaves collagen I, II and III.
RXi Pharmaceuticals president and CEO Geert Cauwenbergh said: "The selection of these two cosmetic product candidates opens the door for additional business development opportunities with both small and large companies that are focusing on non-therapeutic skin health.
"The versatility of MMP1 and TYR, which are relevant for both cosmetic and therapeutic use, are a unique match with our sd-rxRNA platform, allowing us to advance different compounds in both areas of development. This approach further supports our efforts to increase shareholder value."
RXi Pharmaceuticals discovers and develops new therapeutics primarily in the areas of dermatology and ophthalmology for addressing high-unmet medical requirements.
The company’s discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents.